Bionas Signs Service Contract with Solvay Pharmaceuticals
Advertisement
Bionas GmbH announced that it has signed a service contract with Solvay Pharmaceuticals GmbH. The contract covers the metabolic profiling of several drug candidates identified in the context of Solvay´s obesity research program. Financial details were not disclosed.
Solvay has selected the Bionas(r) 2500 analyzing system because it allows monitoring of both acute (short-term) and chronic (long-term) effects of drug candidates in different cell types thanks to a proprietary perfusion system. Besides the long-term observation of cells under close to in vivo conditions, the observation of regeneration effects is also possible.
The Bionas instrument has been also selected by Solvay Pharmaceuticals Research Laboratories for target validation studies.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Unmasking Hidden Potential: LMO4 Enhances T Cell Cancer-Fighting Abilities - Researchers have engineered CD8+ T cells to artificially express the gene LMO4, thereby enhancing their effectiveness against tumors.
Portable device produces biologic drugs on demand
Boehringer Ingelheim Licenses ProBioGen's Novel GlymaxX Technology
Merck Looks Ahead to the Future
Tracking Down Genetic Influences on Brain Disorders
Brain stent offers alternative to shunt for fixing potentially blinding vein narrowing - Pseudotumor cerebri condition marked by excessive pressure in skull, most common in obese, premenopausal women between the ages of 18 and 40